Granted Patent
B2
US 7,718,604 · App. 11/941,092 · Granted May 18, 2010
Use of IL-22 for the treatment of conditions of metabolic disorders
Assignee:
DHY & Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.
Claims (4)
1. A method of reducing serum triglyceride levels, comprising administering to a subject in need of treatment an effective amount of a serum triglyceride level reducing polypeptide consisting essentially of IL-22.
2. The method of claim 1 , wherein the polypeptide consists of isolated, purified IL-22.
3. The method of claim 1 , wherein the serum triglyceride level is associated with or caused by acquired or hereditary obesity.
4. The method of claim 1 , wherein the polypeptide is human IL-22 or mouse IL-22.
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 17, 2015
From: DHY & CO., LTD.
To: GENERON (SHANGHAI) CORPORATION LTD.
Reel/Frame 036584/0462 →
RELEASE OF SECURITY INTEREST
Recorded Apr 28, 2011
From: GENOR BIOPHARMA CO., LTD
To: DHY & CO. LTD
Reel/Frame 026191/0185 →
SECURITY AGREEMENT
Recorded May 6, 2010
From: DHY & CO. LTD.
To: GENOR BIOPHARMA CO., LTD.
Reel/Frame 024342/0051 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF ASSIGNEE FROM PROTCULLIS TRUSTNET CHAMBERS TO PORTCULLIS TRUSTNET CHAMBERS PREVIOUSLY RECORDED ON REEL 020546 FRAME 0058. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST.
Recorded Mar 20, 2008
From: HUANG, YU LIANG; CHEN, XU WEN
To: DHY & CO., LTD
Reel/Frame 020676/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 22, 2008
From: HUANG, YU LIANG; CHEN, XU WEN
To: DHY & CO., LTD
Reel/Frame 020546/0058 →
Priority Claims (1)
CN 2005 1 0023103
· Jan 4, 2005
· national
Continuity (2)
Division
1181328600